Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Open accessPublished version of a preprint
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 2 of the 7 sources its claims cite were checked for support.
Abstract
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, VOC 202012/01 (lineage B.1.1.7), emerged in southeast England in September 2020 and is rapidly spreading toward fixation. Using a variety of statistical and dynamic modeling approaches, we estimate that this variant has a 43 to 90% (range of 95% credible intervals, 38 to 130%) higher reproduction number than preexisting variants. A fitted two-strain dynamic transmission model shows that VOC 202012/01 will lead to large resurgences of COVID-19 cases. Without stringent control measures, including limited closure of educational institutions and a greatly accelerated vaccine rollout, COVID-19 hospitalizations and deaths across England in the first 6 months of 2021 were projected to exceed those in 2020. VOC 202012/01 has spread globally and exhibits a similar transmission increase (59 to 74%) in Denmark, Switzerland, and the United States.
Overview
CoChat Summary
TL;DR
Using sequencing, mobility/contact data, and dynamic transmission models, the paper finds that SARS-CoV-2 lineage B.1.1.7 (VOC 202012/01) spread substantially faster than prior lineages in England. The authors estimate it is 43 to 90% more transmissible, with no clear evidence of increased disease severity, but warn that faster spread would increase cases, hospitalizations, and the need for stronger control measures and faster vaccination.
Key findings
- In UK sequencing data, VOC 202012/01 had the highest relative population growth rate among 307 other lineages in the first 31 days after initial phylogenetic observation, and it continued to expand.
- A multinomial spline model estimated an increased growth rate of +0.104 day–1 relative to B.1.177, corresponding to a 77% increase in reproduction number R (95% CI, 73 to 81%) assuming a 5.5-day generation interval.
- Alternative analyses estimated R for VOC 202012/01 to be 43% higher (95% CI, 38 to 48%) from case-based regression, and 55% higher in Denmark, 74% higher in Switzerland, and 59% higher in the United States.
- The transmission model found no clear increase or decrease in severity, with odds ratios of 0.92 for hospitalization, 0.90 for critical illness, and 0.90 for death, but estimated transmissibility was 65% higher in the three most affected NHS regions and 82% higher across all seven regions.
Methods
- The study combined publicly available sequencing data from COG-UK, Pillar 2 testing data for S gene target failure, mobility data from Google Community Mobility, and social contact data from the CoMix survey, plus analogous sequence/RT-PCR data from Denmark, Switzerland, and the US.
- The authors used multinomial and binomial generalized linear mixed models, negative binomial state-space models, and an age- and region-structured deterministic compartmental transmission model fitted to multiple regional data streams, including deaths, hospital admissions, bed occupancy, PCR prevalence, seroprevalence, and VOC frequency.
- They compared five mechanistic hypotheses for the rapid spread, assessed model fit with deviance information criteria and short-term prediction, and ran scenario projections under varying NPIs and vaccination rollout rates.
Limitations
- The paper states that only a small number of intervention and vaccination scenarios were considered, and these should not be viewed as the only policy options.
- It states that the transmission model does not explicitly capture nursing home or hospital transmission, and regions were fit separately rather than jointly modeling between-region transmission.
- It notes uncertainty in model choice and parameter assumptions, including school-closure assumptions and NPI efficacy; these are limitations stated in the paper.
- Evident from the text: the severity analysis is based on early population-level data up to 24 December 2020, so delays from infection to hospitalization or death could obscure severity effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 2 Measuring the growth rate of VOC 202012/01. (A) Average relativized growth rate (i.e., a measure of variant fitness relative to other variants present during the 31 days after initial phylogenetic observation of a given variant) for all lineages in the COG-UK dataset, highlighting many lineages that have risen to prominence including B.1.177, the lineage with the highest relative abundance during the initial phylogenetic observation of VOC 202012/01. The shaded regions show conservative 95% rejection intervals; VOC 202012/01 is the first strain to exceed this threshold of faster relativized growth. Although many lineages exhibit above-average rates of growth, VOC 202012/01 has had the highest average relativized growth of any lineage in the history of COG-UK surveillance of SARS-COV-2. (B) Plotting all lineages’ relativized growth rates [ρ(t)] as a function of lineage age with conservative 95% rejection intervals highlights the significantly faster growth of VOC 202012/01 relative to other lineages at comparable times since their initial observation. Later declines in VOC and B.1.177 correspond to highly uncertain estimates of growth rates for data that are yet to be backfilled, so these declines in ρ(t) are sensitive to the processing of future sequences from recent dates (fig. S1). (C) Muller plots of the relative abundances of the major SARS-CoV-2 variants in the UK, based on a multinomial spline fit to COG-UK sequence data (Table 1 and table S1, separate-slopes multinomial spline model). A model extrapolation until 1 March 2021 is shown (shaded area). Minority variants are 440 circulating SARS-CoV-2 variants of low abundance. Specific colors represent the same lineages in (A) to (C). (D) Mean reproduction number over 7-day periods in 149 upper-tier local authorities of England (colored by the NHS England region they are within) plotted against the weekly proportion of Pillar 2 community SARS-CoV-2 tests with S gene target failure shows the spread of VOC 202012/01, a corresponding increase in the reproduction number in each local authority, and the eventual impact of targeted government restrictions from 20 December 2020. Testing data are shown for the week after the reproduction number estimates to account for delays from infection to test.](https://figures.cochat.ai/paper-figures/6a959b32b94b41a4aab77f4b47b25a40/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-2.jpg)
![Fig. 3 Comparison of possible biological mechanisms underlying the rapid spread of VOC 202012/01. Each row shows a different assumed mechanism. (A) Relative frequency of VOC 202012/01 (black line and ribbon respectively denote observed S gene target failure frequency with 95% binomial credible interval; purple line and ribbon respectively denote mean and 95% credible interval from model fit). (B) Posterior estimates (mean and 95% credible intervals) for relative odds of hospitalization (severe illness), relative odds of ICU admission (critical illness), relative odds of death (fatal illness), growth rate as a multiplicative factor per week [i.e., exp(7·∆r)], and the parameter that defines the hypothesized mechanism; all parameters are relative to those estimated for preexisting variants. (C to E) Illustrative model fits for the South East NHS England region: (C) fitted two-strain increased transmissibility model with VOC 202012/01 included; (D) fitted two-strain increased transmissibility model with VOC 202012/01 removed; (E) fitted single-strain model without emergence of VOC 202012/01. Black lines denote observed data; error bars denote the date range and 95% credible intervals for observed PCR prevalence and seroprevalence; colored lines and ribbons denote median and 95% credible intervals from model fit.](https://figures.cochat.ai/paper-figures/806d848e45ca40c19e0cc853e2b24dfc/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-3.jpg)

Verification
Claims the paper makes
2 Valid · 0 Not valid · 4 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we did not find substantial differences in social interactions between regions of high and low VOC 202012/01 prevalence, as measured by Google mobility (11) and social contact survey data (12) from September to December 2020 (Fig. 1, E and F).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
What the sources say
- Not matchedcites [11]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Methods (Survey methodology) identify this as the CoMix social-contact survey, supporting the citation’s identification of the survey. But the Results (Participant characteristics) say the data reported here were collected on 24–27 March 2020; this paper does not establish that its reported data cover September–December 2020. The comparison between regions is presented as the citing authors’ own finding, not a finding attributed to this source. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This yielded an estimated increase in R for VOC 202012/01 of 43% (95% CI, 38 to 48%), increasing to a 57% (95% CI, 52 to 62%) increase if the spline was not included (Table 1, models 4a and 4b).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants.”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Discussion Combining multiple behavioral and epidemiological data sources with statistical and dynamic modeling, we estimated that the SARS-CoV-2 variant VOC 202012/01 has a 43 to 90% (range of 95% CrIs, 38 to 130%) higher reproduction number than preexisting variants of SARS-CoV-2 in England, assuming no changes to the generation interval. On the basis of early population-level data, we were unable to identify whether the new variant is associated with higher disease severity. Theoretical considerations suggest that, in some cases, natural selection may favor reduced severity of disease in pathogens (23). For this to be true, however, the pathogen’s infectious period must be truncated by disabling symptoms or death often enough that a less-virulent mutant generates more secondary infections despite potentially being less transmissible per contact, to the extent that decreased virulence and decreased transmissibility are consequences of the same mutation (e.g., one that decreases viral load). It is far from clear that this condition holds for SARS-CoV-2, given substantial transmission before the onset of severe symptoms. Regardless, without strengthened controls, there is a clear risk that future epidemic waves may be larger—and hence associated with greater burden—than previous waves. The UK government initiated a third national lockdown on 5 January 2021 in response to the rapid spread of VOC 202012/01, including school closures. Educational settings are among the largest institutions linked to SARS-CoV-2 clusters that remained open during the November 2020 lockdown (24), which means that the enacted school and university closures may have substantially assisted in reducing the burden of COVID-19 in early 2021. The increase in transmission associated with VOC 202012/01 has crucial implications for vaccination. First, it means that prompt and efficient vaccine delivery and distribution are even more important to reduce the impact of the pandemic in the near future. Increased transmission resulting from VOC 202012/01 will raise the herd immunity threshold, so that the potential burden of SARS-CoV-2 is larger and higher vaccine coverage will be required to achieve herd immunity. It is therefore extremely concerning that VOC 202012/01 has spread to at least 114 countries globally (2). Although VOC 202012/01 was first identified in England, a rapidly spreading variant has also been detected in South Africa (25, 26), where there was a marked increase in transmission in late 2020. Another variant exhibiting immune escape has emerged in Brazil (27, 28). Thus, vaccination timelines will also be a crucial determinant of future burden in other countries where similar new variants are present. Second, there is a need to assess how VOC 202012/01 and other emerging lineages affect the efficacy of vaccines (29, 30). Vaccine developers may need to consider developing formulations with variant sequences, and they may want to initiate post-licensure studies to detect differences in efficacy between the preexisting and new variants. Licensing authorities may need to clarify abbreviated pathways to marketing for vaccines that involve altering strain formulation without any other changes to their composition. There are limitations to our analysis. We have considered a small number of intervention and vaccination scenarios, which should not be regarded as the only available options for policy-makers. Our transmission model does not explicitly capture nursing home or hospital transmission of SARS-CoV-2, and we fit the model to each region of England separately rather than pooling information across regions and explicitly modeling transmission between regions. There are also uncertainties in the choice of model used to generate these predictions, and the exact choice will yield differences in the measures needed to control the epidemic. We note that even without increased susceptibility of children to VOC 202012/01, the more efficient spread of the variant implies that the difficult societal decision of closing schools will be a key public health question for multiple countries in the months ahead. We only assess relative support in the data for the mechanistic hypotheses proposed, but there may be other plausible mechanisms driving the resurgence of cases that we did not consider, and we have not identified the specific combination of mechanisms driving the increased transmission of VOC 202012/01. We identify increased transmissibility as the most parsimonious mechanistic explanation for the higher growth rate of VOC 202012/01, but a longer infectious period also fits the data well (table S4) and is supported by longitudinal testing data (17). Our conclusions about school closures were based on the assumption that children had reduced susceptibility and infectiousness relative to adults (19), but the precise values of these parameters and the impact of school closures remain the subject of scientific debate (31). We based our assumptions about the efficacy of NPIs on the measured impact on mobility of previous national lockdowns in England, but the impact of policy options cannot be predicted with certainty. Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants. Our modeling analysis suggests that this difference could be explained by an overall higher infectiousness of VOC 202012/01, but not by a shorter generation time or immune escape alone. Further experimental work will provide insight into the biological mechanisms for our observations, but given our projections of a rapid rise in incidence from VOC 202012/01—and the detection of other novel and highly transmissible variants (25–28)—there is an urgent need to consider what new approaches may be required to sufficiently reduce the ongoing transmission of SARS-CoV-2.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that the relative population growth rate of VOC 202012/01 in the first 31 days after its initial phylogenetic observation was higher than that of all 307 other lineages with enough observations to obtain reliable growth-rate estimates (Fig. 2A and fig. S1).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
plainn = 150,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of COVID-19 cases attributable to VOC 202012/01 increased rapidly in all regions of England, following an initial expansion in the southeast (Fig. 1A)”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 43 claims and every source verdict.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“B.1.1.7 to be between 43% and 82%3 more transmissible than preexisting variants in the United Kingdom.”
From New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, viral variants of concern have emerged in the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50–55).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several emerging viral variants of concern have been identified that have mutations in the spike protein, including the B.1.1.7 variant (originating from the UK and which has eight spike mutations92), the B.1.351 variant (originating from South Africa) and the P.1 variant (originating from Brazil and which also contains multiple mutations in the spike protein and is spreading widely)57,93.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiological studies suggest that it was approximately 50% more transmissible than previously circulating UK variants 191,197,198 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [198]
The cited source says what the claim attributes to it.
In the citing paper
“it has been previously reported that B.1.1.7 is associated with lower Ct values, corresponding to higher VLs 3”
From Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals (2021) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
Markov Processes: Characterization and Convergence
Ethier, S. N., & Kurtz, T. G. (1986) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316658 · Cited by 3,634
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
Advanced Bayesian Multilevel Modeling with the R Package brms
Bürkner, P.-C. (2018) · The R Journal · doi:10.32614/rj-2018-017 · Cited by 3,015 · cited 9×
“168) 67 (53-83) 120 (92-152) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE North West VOC vs.”
BackgroundMethodInfluentialSocial Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G. S., Wallinga, J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050074 · Cited by 2,900 · cited 10×
“105) 43 (40-46) 72 (67-78) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London VOC vs.”
BackgroundInfluentialSelf-citationProjecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · cited 8×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundResultInfluentialEstimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Self-citationA dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 10×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundInfluential
Cited by
Items 301–400 of 2,327
Zhang, H., Deng, S., Ren, L., Zheng, P., Hu, X., Jin, T., & Tan, X. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109708 · Cited by 71
“How emerging variant viruses rapidly become dominant is a burning question for understanding the dynamics of the epidemic and is critical for vaccine and therapy development (Challen et al., 2021; Davies et al., 2021b; Duffy et al., 2008; Sette and Crotty, 2021).”
One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar
Benslimane, F. M., Al Khatib, H. A., Al-Jamal, O., Albatesh, D., Boughattas, S., Ahmed, A. A., Bensaad, M., Younuskunju, S., Mohamoud, Y. A., Al Badr, M., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.768883 · Cited by 68
Global spatial dynamics and vaccine-induced fitness changes of Bordetella pertussis
Lefrancq, N., Bouchez, V., Fernandes, N. J., Barkoff, A., Bosch, T., Dalby, T., Åkerlund, T., Darenberg, J., Fabianova, K., Vestrheim, D. F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3253 · Cited by 68
SARS-CoV-2: A Master of Immune Evasion
Rubio‐Casillas, A., Redwan, E. M. M. M., & Uversky, V. N. (2022) · Biomedicines · doi:10.3390/biomedicines10061339 · Cited by 79
Molecular evolution of SARS‐CoV‐2 from December 2019 to August 2022
Wolf, J. M., Wolf, L. M., Bello, G. L., Maccari, J. G., & Nasi, L. A. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28366 · Cited by 77
“Concerning transmissibility, this lineage has a higher transmission capacity than previous lineages of SARS‐COV‐2, between 50% and 100% higher.(26,27) Regarding the severity of the disease, the evidence is not conclusive.”
BackgroundRapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6
Taha, T. Y., Chen, I. P., Hayashi, J. M., Tabata, T., Walcott, K., Kimmerly, G. R., Syed, A. M., Ciling, A., Suryawanshi, R. K., Martin, H. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37787-0 · Cited by 75
Early epidemiological signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in EnglandPreprint
Challen, R., Dyson, L., Overton, C. E., Guzman-Rincon, L. M., Hill, E. M., Stage, H. B., Brooks‐Pollock, E., Pellis, L., Scarabel, F., Pascall, D. J., et al. (2021) · medRxiv · doi:10.1101/2021.06.05.21258365 · Cited by 64
Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro
Muñoz‐Basagoiti, J., Perez‐Zsolt, D., León, R., Blanc, V., Regué, D. R., Cano‐Sarabia, M., Trinité, B., Pradenas, E., Blanco, J., Gispert, J., et al. (2021) · Journal of Dental Research · doi:10.1177/00220345211029269 · Cited by 73
“…mouth rinses to reduce the fusion of pseudoviruses displaying different SARS-CoV-2 spikes, including the D614G mutation and the full B.1.1.7 variant, which was originally identified in United Kingdom and whose higher transmissibility and pathogenicity are a global concern (Davies et al. 2021).”
BackgroundInfluentialHetemäki, I., Kääriäinen, S., Alho, P., Mikkola, J., Savolainen‐Kopra, C., Ikonen, N., Nohynek, H., & Lyytikäinen, O. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.30.2100636 · Cited by 72
“7) variant [1], which is more transmissible than the wild-type SARS-CoV-2 virus [2-4].”
BackgroundSARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
Tatsi, E., Filippatos, F., & Michos, A. G. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002430 · Cited by 77
“WHO nomenclature PANGO Lineage Emergence Spike mutations Impact Efficacy of vaccinesCountry Time S1 subunit (1–685aa) S2 subunit (686–1273aa) activity with Covaxin [112] Lambda C.37 Peru December 2020 p.G75V, p.T76I, p.R246del, p.S247del, p.Y248del, p.L249del, p.T250del, p.P251del, p.G252del, p.D253N, p.L452Q, p.F490S…”
BackgroundPirolli, D., Righino, B., Camponeschi, C., Ria, F., Sante, G. D., & Rosa, M. C. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-28716-8 · Cited by 76
SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy
Vinceti, M., Filippini, T., Rothman, K. J., Federico, S. D., & Orsini, N. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111097 · Cited by 75
One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 69
Jhun, H., Park, H., Hisham, Y., Song, C., & Kim, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e32 · Cited by 67
“7 UK Alpha, α H69del, V70del, Y144del, E484K*, S494P*, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, K1191N* VOC (38,39)”
BackgroundSouza, P. F. N., Mesquita, F. P., Amaral, J. L., Landim, P. G. C., Lima, K. R. P., Costa, M. B., Farias, I. R., Belém, M. O., Pinto, Y. O., Moreira, H. H. T., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.058 · Cited by 70
Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets
Haas, K. M., McGregor, M., Bouhaddou, M., Polacco, B. J., Kim, E., Nguyen, T. T., Newton, B. W., Urbanowski, M., Kim, H. J., Williams, M. A. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41442-z · Cited by 70
“More transmissible SARS-CoV-2 variants of concern have continued to emerge, many of which have carried resistance mutations to different monoclonal antibody therapeutics 38 – 42 .”
The RECOVERY Collaborative Group, Horby, P., Estcourt, L. J., Peto, L., Emberson, J., Staplin, N., Spata, E., Pessoa-Amorim, G., Campbell, M. R., Roddick, A., et al. (2021) · medRxiv · doi:10.1101/2021.03.09.21252736 · Cited by 72
Airborne transmission of SARS-CoV-2 in indoor environments: A comprehensive review
Shen, J., Kong, M., Dong, B., Birnkrant, M. J., & Zhang, J. “. (2021) · Science and Technology for the Built Environment · doi:10.1080/23744731.2021.1977693 · Cited by 72
“The Alpha variant was observed 43 to 90% more transmissible than the predecessor lineage (N. Davies et al. 2021).”
BackgroundChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
Fischer, R. J., van Doremalen, N., Adney, D. R., Yinda, C. K., Port, J. R., Holbrook, M. G., Schulz, J. E., Williamson, B. N., Thomas, T., Barbian, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26178-y · Cited by 62
Obéid, M., Suffiotti, M., Pellaton, C., Bouchaab, H., Cairoli, A., Salvadé, V., Stevenel, C., Hottinger, R., Pythoud, C., Coutechier, L., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0446 · Cited by 66
Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
Lin, M.-M., Zeng, X., Duan, Y., Yang, Z., Ma, Y., Yang, H., Yang, X., & Liu, X. (2023) · Communications Biology · doi:10.1038/s42003-023-05071-y · Cited by 65
Kissler, S. M., Fauver, J. R., Mack, C. D., Tai, C. G.-L., Breban, M. I., Watkins, A. E., Samant, R. M., Anderson, D. J., Ho, D. D., Grubaugh, N. D., et al. (2021) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 99
Aldwihi, L. A., Khan, S. I., Alamri, F. F., AlRuthia, Y. S., Alqahtani, F., Fantoukh, O. I., Assiri, A. M., & Almohammed, O. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105086 · Cited by 67
“This is mainly due to the higher transmissibility of SARS-CoV-2 than SARS and MERS and its ability to transform to newer variants that became even more transmissible than the preexisting variants, which has resulted in a larger number of cases and consequently deaths compared to SARS and MERS [6,7].”
ResultInfluentialChen, Y.-T. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147491 · Cited by 68
Zhuang, X., Tsukuda, S., Wrensch, F., Wing, P. A. C., Schilling, M., Harris, J. M., Borrmann, H., Morgan, S. B., Cane, J., Mailly, L., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103144 · Cited by 65
Quantifying the COVID19 infection risk due to droplet/aerosol inhalation
Bale, R., Akiyoshi, I. I. D. A., Yamakawa, M., Li, C., & Tsubokura, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-14862-y · Cited by 66
Rapid and accurate detection of SARS-CoV-2 mutations using a Cas12a-based sensing platform
He, C., Lin, C., Mo, G., Xi, B., Li, A., Huang, D., Wan, Y., Chen, F., Liang, Y., Zuo, Q., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113857 · Cited by 64
SARS-CoV-2 variants – Evolution, spike protein, and vaccines
Chen, K.-W. K., Huang, D. T., & Huang, L. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.04.006 · Cited by 73
Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals
Brizzi, A., Whittaker, C., Servo, L. M. S., Hawryluk, I., Junior, C. A. P., de Souza, W. M., Aguiar, R. S., de Araújo, L. J. T., Bastos, L. S., Blenkinsop, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01807-1 · Cited by 82
Wang, H., Liu, C., Xie, X., Niu, M., Wang, Y., Cheng, X., Zhang, B., Zhang, D., Liu, M., Sun, R., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.007 · Cited by 70
“SARS-CoV-2 Omicron, which exhibits dramatically enhanced transmissibility, is a life-threatening global health issue for individuals with immune deficiencies.(13,14) The high percentage of re-positivity in Omicron patients is an emerging problem, particularly as we have a limited mechanistic understanding of the pheno…”
Gounant, V., Ferré, V. M., Soussi, G., Charpentier, C., Flament, H., Houhou‐Fidouh, N., Collin, G., Namour, C., Assoun, S., Bizot, A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.015 · Cited by 64
Raman Molecular Fingerprints of SARS‐CoV‐2 British Variant and the Concept of Raman Barcode
Pezzotti, G., Boschetto, F., Ohgitani, E., Fujita, Y., Shin‐Ya, M., Adachi, T., Yamamoto, T., Kanamura, N., Marin, E., Zhu, W., et al. (2021) · Advanced Science · doi:10.1002/advs.202103287 · Cited by 63
Lee, Y. S., Wing, P. A. C., Gala, D., Noerenberg, M., Järvelin, A. I., Titlow, J., Zhuang, X., Palmalux, N., Iselin, L., Thompson, M. K., et al. (2021) · eLife · doi:10.7554/elife.74153 · Cited by 61
Multiple COVID-19 Waves and Vaccination Effectiveness in the United States
Lin, L., Zhao, Y., Chen, B., & He, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042282 · Cited by 66
The ins and outs of SARS-CoV-2 variants of concern (VOCs)
Salehi-Vaziri, ., Fazlalipour, M., Khorrami, S. M. S., Azadmanesh, K., Pouriayevali, M. H., Jalali, T., Shoja, Z., & Maleki, A. (2022) · Archives of Virology · doi:10.1007/s00705-022-05365-2 · Cited by 67
Recent Chronology of COVID-19 Pandemic
Siddiqui, S., Alhamdi, H. W. S., & Alghamdi, H. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.778037 · Cited by 81
Chen, S. A., Arutyunova, E. I., Lu, J., Khan, M. B., Rut, W., Żmudziński, M., Shahbaz, S., Iyyathurai, J., Moussa, E. W., Turner, Z., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00054 · Cited by 61
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Nature · doi:10.1038/s41586-024-08511-9 · Cited by 75
“This was evidenced by the emergence of more transmissible variants such as Alpha 4,22,23 and Delta 24,25 .”
Seif, F., Noorimotlagh, Z., Mirzaee, S. A., Kalantar, M., Barati, B., Fard, M. E., & Fard, N. K. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111809 · Cited by 59
Ringlander, J., Fingal, J., Kann, H., Prakash, K., Rydell, G. E., Andersson, M., Martner, A., Lindh, M., Horal, P., Hellstrand, K., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112663119 · Cited by 57
“Mutations occur less commonly in the SARS-CoV-2 genome than in most other RNA viruses, but variants with altered replication efficiency have emerged (15, 16).”
BackgroundNikolaidis, M., Papakyriakou, A., Chlichlia, K., Markoulatos, P., Oliver, S. G., & Amoutzias, G. D. (2022) · Viruses · doi:10.3390/v14040707 · Cited by 75
Tiwari, A., Adhikari, S., Zhang, S., Solomon, T. B., Lipponen, A., Islam, M. A., Thakali, O., Sangkham, S., Shaheen, M. N. F., Jiang, G., et al. (2023) · Water · doi:10.3390/w15061018 · Cited by 63
Rapid replacement of the Beta variant by the Delta variant in South AfricaPreprint
Tegally, H., Wilkinson, E., Althaus, C. L., Giovanetti, M., San, J. E., Giandhari, J., Pillay, S., Naidoo, Y., Ramphal, U., Msomi, N., et al. (2021) · medRxiv · doi:10.1101/2021.09.23.21264018 · Cited by 63
Chen, P., Bobrovitz, N., Premji, Z., Koopmans, M., Fisman, D. N., & Gu, F. (2021) · eLife · doi:10.7554/elife.70458 · Cited by 54
Feldman, J. E., Bals, J., Altomare, C. G., Denis, K. S., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5842 · Cited by 61
Essaidi-Laziosi, M., Alvarez, C., Puhach, O., Sattonnet‐Roche, P., Torriani, G., Tapparel, C., Kaiser, L., & Eckerle, I. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2021806 · Cited by 58
“7) which quickly outcompeted earlier strains in early 2021, then followed by Delta in mid 2021 [13,14].”
BackgroundImpact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland
Shattock, A. J., Rutte, E. A. L., Dünner, R. P., Sen, S., Kelly, S. L., Chitnis, N., & Penny, M. A. (2021) · Epidemics · doi:10.1016/j.epidem.2021.100535 · Cited by 68
Recent insights into SARS‐CoV‐2 omicron variant
da Silva, S. J. R., Kohl, A., Pena, L., & Pardee, K. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2373 · Cited by 61
Increased infections, but not viral burden, with a new SARS-CoV-2 variant
Walker, A. S., Vihta, K.-D., Gethings, O., Pritchard, E., Jones, J., House, T., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., et al. (2021) · doi:10.1101/2021.01.13.21249721 · Cited by 58
Zhang, L., Cui, Z., Li, Q., Wang, B., Yu, Y., Wu, J., Nie, J., Ding, R., Wang, H., Zhang, Y., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02728-4 · Cited by 62
A chitosan-mediated inhalable nanovaccine against SARS-CoV-2
Zhuo, S., Wu, J., Zhao, L., Li, W., Zhao, Y., & Li, Y. (2022) · Nano Research · doi:10.1007/s12274-021-4012-9 · Cited by 58
Modeling COVID-19 dynamic using a two-strain model with vaccination
de León, U. A.-P., Avila-Vales, E. J., & Huang, K. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.111927 · Cited by 62
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
Ryu, D.-K., Song, R., Kim, M., Kim, Y., Kim, C.-M., Kim, J., Kwon, K.-S., Tijsma, A. S. L., Nuijten, P. M., van Baalen, C. A., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.06.016 · Cited by 58
SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence
Dao, T. L., Hoang, V. T., Colson, P., Lagier, J., Million, M., Raoult, D., Levasseur, A., & Gautret, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122635 · Cited by 63
The effect of COVID-19 vaccination in Italy and perspectives for living with the virus
Marziano, V., Guzzetta, G., Mammone, A., Riccardo, F., Poletti, P., Trentini, F., Manica, M., Siddu, A., Bella, A., Stefanelli, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27532-w · Cited by 61
Krueger, T., Gogolewski, K., Bodych, M., Gambin, A., Giordano, G., Cuschieri, S., Czypionka, T., Perc, M., Petelos, E., Rosińska, M., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00084-w · Cited by 60
SARS-CoV-2 transmission dynamics in Belarus in 2020 revealed by genomic and incidence data analysis
Nemira, A., Adeniyi, A. E., Леонидовна, Г. Е., Bulda, K. Y., Valentovich, L. N., Kras’ko, A. G., Glebova, O., Kirpich, A., & Skums, P. (2021) · Communications Medicine · doi:10.1038/s43856-021-00031-1 · Cited by 55
Lim, J., Stavins, R. A., Kindratenko, V., Baek, J. M., Wang, L., White, K., Kumar, J. S., Valera, E., King, W. P., & Bashir, R. (2022) · Lab on a Chip · doi:10.1039/d2lc00021k · Cited by 57
Pondé, R. A. D. A. (2022) · Virology · doi:10.1016/j.virol.2022.05.003 · Cited by 57
“This finding proposed the association of the L452R mutation with the increased infectious capacity of the variant in which the mutation is detected (Deng et al., 2021).”
BackgroundLai, J., Coleman, K. K., Tai, S., German, J. R., Hong, F. H., Albert, B., Esparza, Y., Srikakulapu, A. K., Schanz, M., Maldonado, I. S., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac846 · Cited by 67
CRISPR‐Mediated Profiling of Viral RNA at Single‐Nucleotide Resolution
Chen, D., Huang, W., Zhang, Y., Chen, B., Tan, J., Yuan, Q., & Yang, Y. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202304298 · Cited by 62
The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant
Kimura, I., Yamasoba, D., Nasser, H., Zahradník, J., Kosugi, Y., Wu, J., Nagata, K., Uriu, K., Tanaka, Y., Ito, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105720 · Cited by 54
“529 lineage), and the Alpha variant caused a large surge of infection worldwide beginning in the fall of 2020.(9) Omicron was first reported in South Africa on September 30, 2021 (GISAID ID: EPI_ISL_7971523).”
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Tang, P., Al Kanaani, Z., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003879 · Cited by 54
“7, as suggested elsewhere [46,47], although some studies have suggested otherwise [48,49].”
ResultVerma, J. K., & Subbarao, N. (2021) · Virology · doi:10.1016/j.virol.2021.06.009 · Cited by 56
Kiem, C. T., Massonnaud, C., Lévy-Bruhl, D., Poletto, C., Colizza, V., Bosetti, P., Fontanet, A. L., Gabet, A., Olié, V., Zanetti, L. C. D. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101001 · Cited by 61
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 58
The way of SARS-CoV-2 vaccine development: success and challenges
Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 58
Sandmann, F., Tessier, E., Lacy, J., Kall, M. M., van Leeuwen, E., Charlett, A., Eggo, R. M., Dabrera, G., Edmunds, W. J., Ramsay, M. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac151 · Cited by 54
Self-citationInter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry
Qing, E., Li, P., Cooper, L. M., Schulz, S. R., Jäck, H., Rong, L., Perlman, S. M., & Gallagher, T. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110786 · Cited by 45
“The NTD changes in VOC increase sensitivity to protease-triggered membrane fusion In SARS-CoV-2 VOC, there are substitution mutations in RBDs, in S1-S2 furin cleavage sites, in FDs, and notably also in the NTDs (Davies et al., 2021; Faria et al., 2021; Tegally et al., 2021; Zhang et al., 2021b).”
Are, E. B., Song, Y., Stockdale, J. E., Tupper, P. F., & Colijn, C. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111368 · Cited by 69
Portmann, L., de Kraker, M. E. A., Fröhlich, G., Thiabaud, A., Roelens, M., Schreiber, P. W., Troillet, N., Iten, A., Widmer, A. F., Harbarth, S., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55599 · Cited by 53
Self-citationSARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
Alkhatib, M., Svicher, V., Salpini, R., Ambrosio, F. A., Bellocchi, M. C., Carioti, L., Piermatteo, L., Scutari, R., Costa, G., Artese, A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01096-21 · Cited by 65
From quantum‐derived principles underlying cysteine reactivity to combating the COVID ‐19 pandemic
Mazmanian, K., Chen, T., Sargsyan, K., & Lim, C. (2022) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1607 · Cited by 79
Covid-19: virology, variants, and vaccines
Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 64
Zhan, Y., Lin, Z., Liang, J., Sun, R., Li, Y., Lin, B., Ge, F., Lin, L., Lu, H., Su, L., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102359 · Cited by 55
Andrade, V. M., Christensen-Quick, A., Agnes, J. T., Tur, J., Reed, C., Kalia, R., Marrero, I., Elwood, D., Schultheis, K., Purwar, M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00384-7 · Cited by 56
Model-based evaluation of alternative reactive class closure strategies against COVID-19
Liu, Q.-H., Zhang, J., Cheng, P., Litvinova, M., Huang, S., Poletti, P., Trentini, F., Guzzetta, G., Marziano, V., Zhou, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27939-5 · Cited by 50
“This is even more important in light of the emergence of new variants with possibly higher transmissibility and/or severity (15-17).”
Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach
González‐Parra, G., Martínez‐Rodríguez, D., & Villanueva, R. J. (2021) · Mathematical and Computational Applications · doi:10.3390/mca26020025 · Cited by 59
Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., Lighter, J., Elbel, B. D., Troxel, A. B., & Heguy, A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152702 · Cited by 56
Yaniv, K., Ozer, E., Lewis, Y. E., & Kushmaro, A. (2021) · Water Research · doi:10.1016/j.watres.2021.117808 · Cited by 57
Ayoub, H. H., Mumtaz, G. R., Seedat, S., Makhoul, M., Chemaitelly, H. S., & Abu-Raddad, L. J. (2021) · Global Epidemiology · doi:10.1016/j.gloepi.2021.100068 · Cited by 53
Wotring, J. W., Fursmidt, R. M., Ward, L. S., & Sexton, J. Z. (2022) · Journal of Dairy Science · doi:10.3168/jds.2021-21247 · Cited by 52
“In particular, the South African B.1.351, UK B.1.1.7, Brazilian P.1, and Delta variants have shown to be more virulent and potentially more deadly than previous viral strains (Challen et al., 2021; Davies et al., 2021).”
InfluentialTetz, G. V., & Tetz, V. (2022) · Microorganisms · doi:10.3390/microorganisms10020280 · Cited by 54
Rapid characterization of spike variants via mammalian cell surface display
Javanmardi, K., Chou, C., Terrace, C. I., Annapareddy, A., Kaoud, T. S., Guo, Q., Lutgens, J., Zorkic, H., Horton, A. P., Gardner, E. C., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.024 · Cited by 56
Genetic emergence of B.1.617.2 in COVID-19
Kirola, L. (2021) · New Microbes and New Infections · doi:10.1016/j.nmni.2021.100929 · Cited by 58
“Instead, the B.1.1.7 had already dominated in Britain and >114 countries, including India [9].”
InfluentialSARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a glycoprotein homodimer
Matsuoka, K., Imahashi, N., Ohno, M., Ode, H., Nakata, Y., Kubota, M., Sugimoto, A., Imahashi, M., Yokomaku, Y., & Iwatani, Y. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101724 · Cited by 54
“(2022) 298(3) 101724 presumably has a nonfunctional ORF8 (20, 21), became prevalent in the winter of 2020 (17, 18, 21).”
Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110429 · Cited by 48
“The N501Y Spike mutation increased its affinity for the ACE2 receptor, leading to increased transmissibility (Davies et al., 2021; Prevost et al., 2021; Rambaut et al., 2020).”
Sofonea, M. T., Roquebert, B., Foulongne, V., Morquin, D., Verdurme, L., Trombert‐Paolantoni, S., Roussel, M., Bonetti, J.-C., Zerah, J., Haïm‐Boukobza, S., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2807.220033 · Cited by 56
Lung fibrosis: Post-COVID-19 complications and evidences
Hirawat, R., Jain, N., Saifi, M. A., Rachamalla, M., & Godugu, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109418 · Cited by 56
Tallei, T. E., Fatimawali, F., Yelnetty, A., Idroes, R., Kusumawaty, D., Emran, T. B., Yesiloglu, T. Z., Sippl, W., Mahmud, S., Alqahtani, T., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.717757 · Cited by 53
“7 lineage (UK) has only one mutation at N501Y (Davies et al., 2021; Khan et al., 2021; Madhi et al., 2021; Wang et al., 2021), and the B.”
BackgroundInfluentialAn antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses
Liu, L., Iketani, S., Guo, Y., Reddem, E. R., Casner, R. G., Nair, M. S., Yu, J., Chan, J. F.-W., Wang, M., Cerutti, G., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6859 · Cited by 51
How will mass-vaccination change COVID-19 lockdown requirements in Australia?
Zachreson, C., Chang, S. L., Cliff, O. M., & Prokopenko, M. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100224 · Cited by 53
“[36] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al.”
Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies
Wang, J. J., Zhang, N., Richardson, S. A., & Wu, J. V. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1913123 · Cited by 51
“7 variant is 50% more transmissible [52] that means each case would on average lead to 4.”
BackgroundLives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study
Shoukat, A., VILCHES, T. N., Moghadas, S. M., Sah, P., Schneider, E. C., Shaff, J., Zucker, J. R., Quinn, C., Chokshi, D. A., & Galvani, A. P. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100085 · Cited by 53
Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core
Pak, A. J., Yu, A., Ke, Z., Briggs, J. A. G., & Voth, G. A. (2022) · Nature Communications · doi:10.1038/s41467-022-28654-5 · Cited by 50
“Nonetheless, as these variants also exhibit increased infectivity compared to WT virus 44,45 , we sought to simulate the effects of partial S1/S2 cleavage within the spike trimer on ACE2 binding and S1 dissociation.”
BackgroundSARS‐CoV‐2 virulence evolution: Avirulence theory, immunity and trade‐offs
Alizon, S., & Sofonea, M. T. (2021) · Journal of Evolutionary Biology · doi:10.1111/jeb.13896 · Cited by 59
Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies
Sharun, K., Tiwari, R., Dhama, K., Emran, T. B., Rabaan, A. A., & Mutair, A. S. A. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1923350 · Cited by 53
Puente, J. H. L., Carreño, J. M., Sun, W., Suárez-Martínez, A., Ramírez-Martínez, L. A., Quezada-Monroy, F., la Rosa, G. P.-D., Vigueras-Moreno, R., Singh, G., Rojas-Martínez, O., et al. (2021) · mBio · doi:10.1128/mbio.01908-21 · Cited by 48
Garushyants, S. K., Rogozin, I. B., & Koonin, E. V. (2021) · Communications Biology · doi:10.1038/s42003-021-02858-9 · Cited by 49
SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs
Han, A. X., Toporowski, A., Sacks, J. A., Perkins, M. D., Briand, S. C., Kerkhove, M. D. V., Hannay, E., Carmona, S., Rodriguez, B., Parker, E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-022-01267-w · Cited by 57
Metadata
- Authors
- Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites, W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M., Funk, S., Jit, M., Atkins, K. E., & Edmunds, W. J.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Selva Analytics LLC, Bozeman, MT, USA.
- KU Leuven (BE)
- Pennsylvania State University (US)
- Centre for Statistical Methodology and Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
- Corresponding author
- Davies, Nicholas G.
- ORCID
- Davies, Nicholas G.
- Abbott, Sam
- Barnard, Rosanna C.
- Jarvis, Christopher I.
- Kucharski, Adam J.
- Munday, James D.
- Pearson, Carl A. B.
- Russell, Timothy W.
- Tully, Damien C.
- Washburne, Alex D.
- Wenseleers, Tom
- Gimma, Amy
- Waites, William
- Wong, Kerry L. M.
- van Zandvoort, Kevin
- Silverman, Justin D.
- Diaz-Ordaz, Karla
- Keogh, Ruth
- Eggo, Rosalind M.
- Funk, Sebastian
- Jit, Mark
- Atkins, Katherine E.
- Edmunds, W. John
- Venue
- Science
- Published
- 2021-04-09
- Volume
- 372
- Issue
- 6538
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8128288
- OpenAlex
- W3134208712
- Semantic Scholar
- 34e9a0b4e42a4971a3a124c818045741c734fb9e
- Cited by
- 2,581
- References
- 58
- Citations by year
- 2026: 74 · 2025: 102 · 2024: 199 · 2023: 330 · 2022: 840 · 2021: 1028
- FWCI
- 215.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (submittedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion, cc-by)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- University of Kentucky
- Universität Bern
- Universitätsspital Basel
- National Institute for Health Research (NIHR200908)
- European Commission (101003688)
- CANDU Owners Group
- Hôpitaux Universitaires de Genève
- Eidgenössische Technische Hochschule Zürich
- Université de Sfax
- UKRI Research England (NA)
- National Institute for Health Research Health Protection Research Unit in Immunisation (NIHR200929)
- United Kingdom Medical Research Council (MC_PC_19065)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- SARS-CoV-2, B.1.1.7 variant, reproduction number, SARS-CoV-2 transmission, epidemic forecasting, COVID-19 containment measures, vaccine rollout, school closures, England
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Communicable Disease Control, England, Europe, Female, Humans, Infant, Male, Middle Aged, Models, Theoretical, Mutation, Severity of Illness Index, Socioeconomic Factors, United States, Viral Load, Basic Reproduction Number, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.